商品名：Fragmin and LMWH
Low-molecular-weight heparin (LMWH), also known as fragmented heparin. LMWH is characterized by a molecular weight of approximately 5000, compared to conventional heparin (unfractionated, or UFH) with a molecular weight of approximately 15,000. Subsequently, the absorption, clearance, and activity of LMWH differ from UFH. LMWHs produce their effect by binding to antithrombin (AT) and increasing antithrombin III–mediated inhibition of synthesis and activity of coagulation factor Xa. However, LMWH, unlike conventional heparin, produces less inhibition of thrombin (factor IIa). LMWH’s activity is described by the Anti-factor Xa/Anti-factor IIa ratio. For dalteparin, the ratio is 2.7 : 1 (conventional unfractionated heparin ratio is 1 : 1). In people, LMWHs have several advantages compared to
Dalteparin, like other LMWHs, is used to treat hypercoagulability disorders and prevent coagulation disorders such as thromboembolism, venous thrombosis, disseminated intravascular coagulopathy (DIC), and pulmonary thromboembolism. Clinical indications are derived from uses of conventional heparin or extrapolated from human medicine. There have been few clinical studies to examine efficacy of LMWH in animals. Previously published doses extrapolated from humans (100 units/kg q12h, SQ) have been shown not to produce adequate and consistent anti-Xa activity in dogs and cats and the doses listed in this entry are needed for therapy.
劑量數字暫停提供：VetPro 的劑量改依 DRUGAPI 藥物資料庫對外的內容，DRUGAPI 目前不提供可直接計算的劑量。下方列出 DRUGAPI 的審查結論與劑量審查引用的來源；計算機可手動輸入劑量換算。
執行前必須由獸醫確認精確 dalteparin sodium 產品、濃度與防腐劑狀態、物種與族群、血栓適應症與出血風險、實際途徑、體重與計量單位、腎肝功能、血小板與 HIT 病史、近期手術或神經軸處置、完整共用藥、基線與追蹤監測、抗 Xa 檢驗方法與採樣時間、出血救援能力，以及適用法域與食用動物責任；任何一項未閉合即不得產生可執行輸出。
87%
renal